arrow
E

Emma Iserman

mcmaster university
H指数:11
被引数:3,896

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative safety of drug therapies used hemophilia A and B in Canada: a multi-center, retrospective study

加拿大用于血友病A和B的药物疗法比较安全性:一项多中心、回顾性研究

2025-12-020
OAAI
Canadian Clinical Experience on Switching From Standard Half-life Recombinant Factor VIII (rFVIII), Octocog Alfa, to Extended Half-life rFVIII, Damoctocog Alfa Pegol, in Persons With Haemophilia A ≥ 12 Years Followed in a Comprehensive Haemophilia Care Program in Canada

加拿大临床经验:在加拿大综合血友病护理计划中,≥12岁的血友病A患者从标准半衰期重组FVIII(rFVIII),Octocog Alfa,转换为长效半衰期rFVIII,Damoctocog Alfa Pegol。

2025-10-140
PRE
Feasibility of Administering the Patient Reported Outcomes, Burdens and Experiences (PROBE) Questionnaire Through the Canadian Bleeding Disorders Registry (CBDR) and Comparison of Data From the Two Sources

通过加拿大出血性疾病登记系统(CBDR)实施患者报告结局、负担和经历(PROBE)问卷的可行性,以及对两种来源数据的比较

2025-08-280
OAAI
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada

加拿大在血友病A ≥ 12年的人群中从标准半衰期重组因子VIII (rFVIII),octocog alfa转换为延长半衰期rFVIII,damocog alfa pegol的临床经验,随后在加拿大进行了全面的血友病护理计划

2024-02-204
OA
Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes

在血友病B中治疗改用nonacog β pegol因子IX: 基于真实世界因子IX消耗和临床结果的加拿大成本后果分析

2023-03-013
OAAI
Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real-world, multicenter, retrospective study

在血友病B中改用nonacog β pegol: 来自加拿大现实世界,多中心,回顾性研究的结果

2022-03-019
OAAI